Search Results

91 - 100 of 282 items :

  • pharmacokinetics x
  • Clinical Medicine x
Clear All
Lipophilic chemical exposure as a cause of cardiovascular disease

). Abosrption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrobial Agents and Chemotherapy 54 (1): 570-572. Rea, WJ. (1992). Chemical sensitivity, vol I. Lewis Publishers , Boca Raton. Reddy L, Bhoola K. (2010). Ochratoxins - food contaminants: impact on human health. Toxins 2 : 771-779. Rosenman KD. (1979). Cardiovascular disease and environmental exposure. Br J Ind Med 36 : 85-97. Rufer ES, Hacker TA, Flentke GR, Drake VJ, Brody MJ, Lough J, Smith SM. (2010). Altered

Open access
Natural flavonoids as potential multifunctional agents in prevention of diabetic cataract

transport of quercetin glycosides in rats involves both deglycosylation and interaction with the hexose transport pathway. J Nutr   130 : 2765-2771. Giacco F, Brownlee M. (2010). Oxidative stress and diabetic complications. Circ Res   107 : 1058-1070. Grotte D, Mattox V, Brubaker R. (1985). Fluorescent, physiological and pharmacokinetic properties of fluorescein. Exp Eye Res   40 : 23-33. Gupta SK, Halder N, Srivastava S, Trivedi D, Joshi S, Varma SD. (2002). Green tea (Camellia sinensis

Open access
New frontiers of target therapy in oncology: acute promyelocytic leukemia

advances in the acute promyelocytic leukemia. Int J Hematol 2002; 76 (suppl2): 179-87. http://dx.doi.org/10.1007/BF03165115 77. Shen Z-X, Chen G-Q, Ni J-H, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89 (9): 3354-60. 78. Au WY, Lie AK, Chim CS, et al. Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukemia. Ann Oncol 2003; 14 (5

Open access
Toxicity of lead: a review with recent updates

damage and apoptosis induced by lead. Environ Toxicol Pharmacol 30: 264-271. Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. (2007). Curcuminphospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm 330: 155-163. Mates JM. (2000). Eff ects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 153 : 83-104. Mozafari MR, Flanagan J, Matia-Merino L, Awati A, Omri A, Suntres Z, Singh H. (2006). Recent trends in the lipid

Open access
Evidence of growth hormone effect on plasma leptin in diet-induced obesity and diet-resistant rats

JM Halaas JL Leptin and the regulation of body weight in mammals Nature 1998 395 763 70 [3] Ahren B, Baldwin RM, Havel PJ. Pharmacokinetics of human leptin in mice and rhesus monkeys. Int J Obes Relat Metab Disord. 2000; 24:1579–85. 10.1038/sj.ijo.0801447 11126209 Ahren B Baldwin RM Havel PJ Pharmacokinetics of human leptin in mice and rhesus monkeys Int J Obes Relat Metab Disord 2000 24 1579 85 [4] Bodosi B, Gardi J, Hajdu I, Szentirmai E, Obal F Jr., Krueger JM. Rhythms of ghrelin, leptin, and sleep in rats: effects of the

Open access
Exposure to lipophilic chemicals as a cause of neurological impairments, neurodevelopmental disorders and neurodegenerative diseases

, Wachall B, Doroshyenko O, Tomalik-Scharte D, Bastian B, et al. (2010). Absorption, pharmacokinetics, and safety of triclosan after dermal administration. Antimicrobial Agents and Chemotherapy 54 (1): 570-572. Qiu C, cheng S, Xia Y, Peng B, Tang Q, Tu B. (2011). Eff ects of subchronic benzo(a)pyrene exposure on neurotransmitter receptor gene expression in the rat hippocampus related with spatial learning and memory change. Toxicology 289 (2-3): 83-90. Ren A, Qiu X, Jin J, Li Z, Ma J, Zhiwen L, et al. (2011). Association of selected

Open access
How specialist nurse-led care can help to lower the costs of prophylaxis

References 1 Richards M, Williams M, Chalmers E et al. A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematology 2010; 149: 498;507. 2 Morfini M. Pharmacokinetics of factor VIII and factor IX. Haemophilia 2003; 9 <Suppl 1=: 94;9.. 3 Bjorkman S. Prophylactic dosing of factor VIII and factor IX from a clinical

Open access
Oral treatment with etoposide in small cell lung cancer – dilemmas and solutions

. Pharmacokinetic optimisation of treatment with oral etoposide. Clin Pharmacokinet 2004; 43: 441-6. 13. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252: 9-18. 14. Hande KR. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Oncologist 1996; 1: 234-9. 15. Greco FA, Johnson DH, Hande KR, Porter LL, Hainsworth JD, Wolff SN. High-dose etoposide (VP-16) in small-cell lung cancer. Semin Oncol 1985; 12(Suppl 2): 42-4. 16. Slevin ML

Open access
Direct Oral Anticoagulant Drugs in Dental Clinical Practice

Abstract

The direct oral anticoagulant drugs (DOAC) are generally safe and effective in several clinical settings including acute venous thromboembolic disease, prophylaxis in the postoperative setting, prevention of thromboembolism in patients with non-valvular atrial fibrillation, and in the management of acute coronary syndrome. The relatively short half-life, rapid onset of action, and predictable pharmacokinetics should simplify periprocedural use of the DOAC. The aim of this work is to propose and summarize periprocedural management of patients treated with the DOAC in dental practice and to inform about the principal specifications of this treatment.

Open access
Morphological and pharmacokinetic properties of oral solid dietary supplements containing plant extracts

Summary

Introduction: Dietary supplements are a good way to supplement the deficiency of certain micronutrients and organic components (therapeutic agents) in human body. They are most often available in concentrated form as tablets, capsules, powder or liquid.

Objective: To investigate morphological parameters and the pharmaceutical availability of coated tablets – dietary supplements – that contain selected pharmacopeial titrated dry plant extracts.

Methods: Testing of the effective time of the tablet surface erosion was performed in model acceptor fluids using pharmacopeial methods in static (Erweka apparatus) and dynamic (unlimited diffusion method) conditions. Furthermore, morphological parameters of tablets (the original shape of an ellipse) as well as their hardness were determined.

Results: The effective erosion time was determined by conductometric method using carboxymethylcellulose sodium salt (NaCMC) contained in the tablet. The content of gum arabic and NaCMC in the tablet testifies that the granulate was produced using the “wet granulation” technique which resulted in high hardness of original, esthetic, elliptical tablets and in prolonged disintegration time (erosion).

Conclusions: The used excipients: gum arabic and NaCMC for the production of the tested tablets containing selected dry plant extracts result in their high hardness. The tested dietary supplements are characterized by esthetic design, original shape, and prolonged disintegration time which affects the pharmaceutical availability.

Open access